Murlentamab

莫伦妥单抗

Report date: 2026/02/10 20:00:22

Base Information

Drug NameMurlentamab
Drug Alias NameHumanised monoclonal antibody 3C23KAnti-MISRII humanised monoclonal antibody 3C23K3C23-KGM-102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Mullerian hormone receptor II antagonists
TargetsAnti-Mullerian hormone receptor II
Therapy Area/IndicationsGenital Neoplasms, FemaleColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLfb Biotechnologies Sas
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGamamabs PharmaExelixis Inc
Active IndicationsN/A
Inactive IndicationsGenital Neoplasms, FemaleColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A